Loading provider…
Loading provider…
Hematology & Oncology Physician in San Diego, CA
NPI: 1215285770Primary Employer
UCSD Medical Group
health.ucsd.edu
HQ Phone
Get MD Kay's Phone Numberphone_androidMobile
Get MD Kay's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2013 - 2027

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Medical Oncology
University of California (San Diego) Medical Center
Fellowship • Hematology and Medical Oncology
2015 - 2017
Residency • Internal Medicine
2012 - 2014
New York University School of Medicine
Medical School
Until 2012
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 84 | 115 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 56 | 132 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 17 | 17 |
Authors: Rebecca Shatsky, Laura Esserman, Elissa Price, Carla Falkson, Karthik Giridhar, Tara Sanft, Mariya Rozenblit, Laura Huppert, Margaret Blackwood, Erica Stringer-Reasor, Sarah Boles, Angela Demichele, Brittani Thomas, Anne Wallace, Frederick Howard, Mili Arora, Rita Nanda, Paula Pohlmann, Amy Clark, Anthony Elias, Amy Sanford, Meghna Trivedi, Jennifer Tseng, Chaitali Nangia, Heather Beckwith
Journal: Nat Med
Publication Date: 2024-09-14
Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Intervention / Treatment: DRUG: Placebo, DRUG: Trastuzumab, DRUG: Pertuzumab, DRUG: Tucatinib, DRUG: Combination product: Trastuzumab + Pertuzumab
Lead Sponsor: Dantari, Inc.
Intervention / Treatment: DRUG: Niraparib, DRUG: DAN-222
Lead Sponsor: Jazz Pharmaceuticals
Collaborators: ALX Oncology Inc.
Intervention / Treatment: DRUG: Evorpacept, DRUG: Zanidatamab